| Cat. No. |
Product Name |
Information |
| PC-38115 |
SLC6A19 inhibitor 39
SLC6A19 inhibitor
|
SLC6A19 inhibitor 39 is a potent, selective and orally efficacious inhibitor of neutral amino acid transporter B0AT1 (SLC6A19) with IC50 of 35 nM. |
| PC-38114 |
T-690
Glucosylceramide synthase inhibitor
|
T-690 is a potent, selective, oral inhibitor of glucosylceramide synthase (GCS) with IC50 of 15 nM. |
| PC-38105 |
RA5557
UGT8 inhibitor
|
RA 5557 is a brain-penetrant, selective, oral UGT8 inhibitor, inhibits galactosylceramide biosynthesis. |
| PC-38098 |
PXS-5129A
LOXL2 inhibitor
|
PXS-5129A is the pro-drug form of PXS-5120A, a potent, selective, irreversible inhibitor of Lysyl oxidase-like 2 (LOXL2). |
| PC-38097 |
PXS-5120A
LOXL2 inhibitor
|
PXS-5120A is a potent, selective, irreversible inhibitor of Lysyl oxidase-like 2 (LOXL2) with IC50 of 5 and 6 nM (hLOXL2 and mLOXL2). |
| PC-38093 |
MSDC-0602
MPC inhibitor
|
MSDC-0602 (Azemiglitazone) is a PPARγ-sparing thiazolidinedione insulin sensitizer, targets mitochondrial pyruvate carrier protein (MPC) Mpc1 and Mpc2. |
| PC-38092 |
MSDC-0602K
|
MSDC-0602K (Azemiglitazone) is a PPARγ-sparing thiazolidinedione insulin sensitizer, targets mitochondrial pyruvate carrier protein (MPC) Mpc1 and Mpc2. |
| PC-38091 |
SM-102
|
SM-102 is an amino cationic lipid that has been tailored for the formation of lipid nanoparticles, and one of the essential ingredients present in the ModernaTM COVID-19 vaccine. |
| PC-38088 |
Lobaplatin
|
Lobaplatin (D-19466) is an antitumour platinum agent containing a 1,2-bis(aminomethyl)cyclobutane stable ligand and lactic acid as the leaving group.. |
| PC-38061 |
DFO-5
|
DFO-5 (Oseltamivir Epoxy Impurity) is an oseltamivir impurity. |
| PC-38055 |
DiI
|
Dil (DiIC18(3)) is a fluorescent neuronal tracer that labels cell bodies, axons, dendrites, and dendritic spines. |
| PC-38046 |
Lipid L319
|
L-319 (O-8670) is an ionizable (pKa = 6.38) and biodegradable lipid that has been used in the formation of lipid nanoparticles. |
